Samjin Pharmaceutical Co Ltd
KRX:005500
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Samjin Pharmaceutical Co Ltd
Cash from Financing Activities
Samjin Pharmaceutical Co Ltd
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Samjin Pharmaceutical Co Ltd
KRX:005500
|
Cash from Financing Activities
₩11.4B
|
CAGR 3-Years
-38%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Yuhan Corp
KRX:000100
|
Cash from Financing Activities
₩8B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-18%
|
|
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Cash from Financing Activities
-₩156.7B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Hanmi Pharm Co Ltd
KRX:128940
|
Cash from Financing Activities
-₩97.2B
|
CAGR 3-Years
-38%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Cash from Financing Activities
₩22.8B
|
CAGR 3-Years
20%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
C
|
Caregen Co Ltd
KOSDAQ:214370
|
Cash from Financing Activities
-₩31.2B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
Samjin Pharmaceutical Co Ltd
Glance View
Samjin Pharmaceutical Co., Ltd. engages in the manufacture, distribution, and sale of pharmaceutical products. The company is headquartered in Seoul, Seoul and currently employs 755 full-time employees. The Company’s products include antipyretics, analgesics, antiphlogistic agents, osteoarthritis agents, osteopathic agents, antihistaminic agents, circulatory system drugs, gastrointestinal agents, osteoporosis treatments, hepatic disease agents, respiratory agents, antibiotics agents, detoxifying agents, antifungal agents, antineoplastic agents and others. Its products are provided in the forms of tablets, injections, capsules and others. The company distributes its products to the hospitals and drugstores. The firm supplies its products within domestic market and to overseas markets.
See Also
What is Samjin Pharmaceutical Co Ltd's Cash from Financing Activities?
Cash from Financing Activities
11.4B
KRW
Based on the financial report for Dec 31, 2025, Samjin Pharmaceutical Co Ltd's Cash from Financing Activities amounts to 11.4B KRW.
What is Samjin Pharmaceutical Co Ltd's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 3Y
-38%
The average annual Cash from Financing Activities growth rates for Samjin Pharmaceutical Co Ltd have been -38% over the past three years .
